Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma.
Mol. Pharm., Jun;9(6):1727-35 (2012)
The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner.
J Hematol Oncol., 4:49 (2011)
The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone.
Cancer Immunol. Immunother., Jun;60(6):771-80 (2011)
Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders.
Autoimmun Rev., Mar;9(5):A335-41 (2010)
Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts.
Cancer Immunol. Immunother., Dec;58(12):2051-8 (2009)
Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy.
Cancer Immunol. Immunother., Oct;58(10):1715-22 (2009)
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
Blood., May;101(9):3641-7 (2003)
Applications of one-bead one-compound combinatorial libraries and chemical microarrays in signal transduction research.
Acc. Chem. Res., Jun;36(6):370-7 (2003)
Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma.
Leuk. Res., Feb;28(2):179-90 (2004)
B lymphocytes contribute to autoimmune disease pathogenesis: current trends and clinical implications.
Autoimmun Rev., Mar;2(2):101-8 (2003)
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human
Clin. Cancer Res., Aug;11(16):5920-7 (2005)
B cell reductive therapy in the treatment of autoimmune diseases: a focus on monoclonal antibody treatment of rheumatoid arthritis.
Hematology., Dec;10(6):521-7 (2005)
Phosphorylation abnormalities: NZB mice exhibit a B-cell signalling defect.
J. Autoimmun., Nov;19(3):103-9 (2002)
Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
Clin. Cancer Res., May;16(10):2760-8 (2010)
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD).
Invest New Drugs., Jun;28(3):260-7 (2010)
Imaging and pharmacokinetics of (64)Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin's lymphoma xenografts.
Mol Imaging Biol., 11(2):79-87 (2009)
CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade.
Blood., Aug;94(4):1382-92 (1999)
Prognostic factors and response to fludarabine therapy in patients with WaldenstrÃ¶m macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).
Blood., Jul;98(1):41-8 (2001)
Radioimmunotherapy: potential as a therapeutic strategy in non-Hodgkin's lymphoma.
BioDrugs., 15(3):151-62 (2001)
Co-Author, "Lenalidomide oral mono therapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma."
British Journal of Haematology